EAM Investors’s aTyr Pharma ATYR Stock Holding History

EAM Investors’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-252,280	Closed	-$1.89M	–	403
2021 Q4	$1.89M	Sell	252,280 -7,511	-3%	-$62.7K	0.31%	141
2021 Q3	$2.36M	Buy	+259,791	New	+$1.55M	0.4%	79

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

EAM Investors's ATYR Position: Q1 2022 in Review

EAM Investors sold out of aTyr Pharma (ATYR) in Q1 2022, closing a stake of 252,280 shares — an estimated $1.89M sold.

EAM Investors first reported a position in ATYR in Q3 2021 and held it in 2 quarters. The position peaked at $2.36M in Q3 2021. 41 funds tracked by Wall St. Rank hold ATYR as of Q1 2022.

EAM Investors reported no remaining aTyr Pharma position as of Q1 2022 after selling out during the quarter.
EAM Investors sold 252,280 aTyr Pharma shares in Q1 2022, an estimated $1.89M.
EAM Investors first reported a position in aTyr Pharma in Q3 2021 and held it in 2 quarters.
EAM Investors's aTyr Pharma position peaked at $2.36M in Q3 2021.
41 funds tracked by Wall St. Rank held aTyr Pharma as of Q1 2022.

Based on EAM Investors's 13F filing for Q1 2022, filed 13 May 2022.